✦ LIBER ✦

Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma

✍ Scribed by William I. Bensinger; Sundar Jagannath; Robert Vescio; Elber Camacho; Jeffrey Wolf; David Irwin; Gerardo Capo; Marti McKinley; Phyllis Potts; David H. Vesole; Amitabha Mazumder; John Crowley; Pam Becker; Jacqueline Hilger; Brian G.M. Durie

Book ID: 108676581
Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 155 KB
Volume: 148
Category: Article
ISSN: 0007-1048
DOI: 10.1111/j.1365-2141.2009.07981.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Bortezomib, doxorubicin, and dexamethaso

Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety

✍ Sung Sook Lee; Cheolwon Suh; Bong-Seog Kim; Jooseop Chung; Young-Don Joo; Hun-Mo 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 151 KB

Sequential vincristine, adriamycin, dexa

Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial

✍ Hye Jin Kim; Sung-Soo Yoon; Dong Soon Lee; Sang Kyun Sohn; Hyeon Seok Eom; Jung 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 184 KB

Extended follow-up of a phase 2 trial of

Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma

✍ Sundar Jagannath; Brian G. M. Durie; Jeffrey Lee Wolf; Elber S. Camacho; David I 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 209 KB